Founding Metamorphosis-Tx
December 20, 2023. Metamorphosis-Tx was founded as a joint venture subsidiary of DCDC-Tx. Metamorphosis is dedicated to develop cancer differentiation therapy. BioDetection Systems (BDS) is co-founder of Metamorphosis. The unique CALUX-STP technology of BDS complements STAP-STP technology of DCDC-Tx.
Below you find information on our core team and advisory board.
Team
Clinical, cell biology/molecular biology, stem cell biology, preclinical/clinical drug development, IP, legal, business expertise
founder, CSO (Chief Scientific Officer): Anja van de Stolpe
Dr. Anja van de Stolpe is an internist with clinical, translational, preclinical drug repurposing, and entrepreneurial experience. PhD degree in cell and molecular biology at the Hubrecht Institute (Utrecht, The Netherlands), post-doc at Stanford University.
She is an inventor on a large number of patents, including the STP portfolio.
For publications, see Selected Publications and ResearchGate. For CV details, see LinkedIn.
FOUNDER, COO (CHIEF OPERATING OFFICER): BRAM BROUWER
Chief Operational Officer: Em. Professor Abraham Brouwer, CEO BDS, studied Chemistry in Leiden and obtained a PhD in Medicine; he has over 30 years of experience as licensed toxicologist and held a chair position in Environmental Toxicology and Ecogenomics at VU University Amsterdam. He is the inventor of the CALUX technology. For CV and publications, see LinkedIn and ResearchGate.
FOUNDER, CMO (Chief Medical Officer): Reinier Raymakers
Dr Reinier Raymakers is a clinical hematologist, with focus on hemato-oncology, with extensive translational research (11 PhD theses), and clinical drug development experience.
PhD degree on Autologous Bone Marrow Transplantation for malignancies, post-doc at Roswell Park Cancer Institute (Buffalo, NY) and University Medical Center Leiden (The Netherlands). Clinical staff member at the academic hematology department UMC Radboud and UMC Utrecht. For publications, see Selected Publications and ResearchGate. For CV details, see LinkedIn.
FOUNDER, CEO (Chief Executive Officer): Frans Bos, PhD Physics, LLM
Extensive managerial experience at Executive level in a broad portfolio of fields
FOUNDER, CFO (Chief Financial Officer): YVETTE VAN SCHEPPINGEN
FOUNDER: Jan Karel van der Staay, LLM
Former General Counsel. Extensive governance, legal and M&A experience at Board level. For CV details, see LinkedIn.
Business Development: Alex Klijn (Alex Consultancy), Palo Alto, US
Alex obtained a Master in econometrics at the University of Amsterdam, followed by six years of professional experience at Roland Berger in strategy and management consultancy for leading (inter)national companies in Technology and Financial services, including two years of experience in venture building and business development primarily for Medical/Health Technology startups. December 2024 Alex moved to Palo Alto (US) and founded Alex Consultancy for Tech companies. Also see Linkedin.
Advisory board
Prof. Stefanie Jeffrey, MD, Stanford University, US
Stefanie Jeffrey, MD, is the John and Marva Warnock Professor, Emerita and former Chief of Surgical Oncology Research in the Department of Surgery at Stanford University School of Medicine. She received her undergraduate degree in Chemistry and Physics and master’s degree in Chemistry from Harvard University. She graduated from medical school at University of California San Francisco (UCSF), where she also completed her surgical residency. Her lab focused on technology development and applications related to liquid biopsy (CTCs, ctDNA, extracellular vesicles), droplet-based microfluidic platforms, and preclinical models for testing new cancer therapies. Also see LinkedIn.
Prof. Pim French, PhD, ErasmusMC, The Netherlands
Pim French is Professor of the Department of Neurology, ErasmusMC, in Rotterdam. He studied medical biology and was post-doc at the National Institute for Medical Research, London, UK. Pim specialized in molecular biology of gliomas, he is founder of the Cancer Treatment Screening Facility, member of the EANO scientific committee, and EORTC brain tumor group. Also see LinkedIn.
Prof. Dirk de Ruysscher, MD, PhD, Maastro/MaastrichtUMC and ErasmusMC, The Netherlands
Dr. De Ruysscher earned his medical degree at the University of Leuven, Belgium, in 1986, and became Radiation Oncologist at the same university in 1991. In 1992, he obtained his PhD thesis at the University of Leuven on the influence of radiotherapy on immunity. At present, Dr. De Ruysscher is full Professor of Radiation Oncology/ Respiratory Oncology both at the Maastricht University Medical Center, Maastricht, and at Erasmus MC, Rotterdam, The Netherlands.
He heads of the Division Maastro Clinical Research, chairs the EORTC Lung Cancer Group/ Oligometastatic and new development group and was the former chair of DUPROTON (the Dutch organization for proton therapy research) and of the Dutch Platform for Radiotherapy of Lung Cancer. He has been or is the lead PI of 7 phase I studies, 23 phase II and 9 phase III trials. Dr. De Ruysscher published more than 500 peer-reviewed Wi-1 papers and chapters in several scientific books and has a H-index of 105, a i10-index of 408 and 40080 citations. Also see LinkedIn.